AR040134A1 - Formulacion para la administracion parenteral de un bloqueante del canal del na - Google Patents

Formulacion para la administracion parenteral de un bloqueante del canal del na

Info

Publication number
AR040134A1
AR040134A1 ARP030101863A ARP030101863A AR040134A1 AR 040134 A1 AR040134 A1 AR 040134A1 AR P030101863 A ARP030101863 A AR P030101863A AR P030101863 A ARP030101863 A AR P030101863A AR 040134 A1 AR040134 A1 AR 040134A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
composition according
acid
yeta
cyclodextrin
Prior art date
Application number
ARP030101863A
Other languages
English (en)
Spanish (es)
Inventor
Karin Ruehr
Jean Marie Stassen
Claus Veit
Kruss Bernd Dr
Annerose Mauz
Wagner Klaus Dr
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR040134A1 publication Critical patent/AR040134A1/es

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP030101863A 2002-05-29 2003-05-28 Formulacion para la administracion parenteral de un bloqueante del canal del na AR040134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10223783A DE10223783A1 (de) 2002-05-29 2002-05-29 Neue Formulierung zur parenteralen Applikation eines Na-Kanal-Blockers

Publications (1)

Publication Number Publication Date
AR040134A1 true AR040134A1 (es) 2005-03-16

Family

ID=29432393

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101863A AR040134A1 (es) 2002-05-29 2003-05-28 Formulacion para la administracion parenteral de un bloqueante del canal del na

Country Status (12)

Country Link
EP (1) EP1511517B1 (cg-RX-API-DMAC7.html)
JP (1) JP2005527615A (cg-RX-API-DMAC7.html)
AR (1) AR040134A1 (cg-RX-API-DMAC7.html)
AT (1) ATE373492T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003237664A1 (cg-RX-API-DMAC7.html)
CA (1) CA2487150A1 (cg-RX-API-DMAC7.html)
DE (2) DE10223783A1 (cg-RX-API-DMAC7.html)
ES (1) ES2294295T3 (cg-RX-API-DMAC7.html)
PE (1) PE20040066A1 (cg-RX-API-DMAC7.html)
TW (1) TW200400029A (cg-RX-API-DMAC7.html)
UY (1) UY27823A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003099336A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
FR2713934B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de cyclodextrines aminées pour la solubilisation aqueuse de composés hydrophobes, en particulier de molécules pharmaceutiquement actives.
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US6565880B2 (en) * 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
DE10223784A1 (de) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma Neue Formulierung zur parenteralen Applikation von Crobenetine

Also Published As

Publication number Publication date
DE50308227D1 (de) 2007-10-31
DE10223783A1 (de) 2003-12-11
EP1511517A1 (de) 2005-03-09
ES2294295T3 (es) 2008-04-01
JP2005527615A (ja) 2005-09-15
AU2003237664A1 (en) 2003-12-12
EP1511517B1 (de) 2007-09-19
PE20040066A1 (es) 2004-03-22
ATE373492T1 (de) 2007-10-15
WO2003099336A1 (de) 2003-12-04
CA2487150A1 (en) 2003-12-04
UY27823A1 (es) 2003-12-31
TW200400029A (en) 2004-01-01

Similar Documents

Publication Publication Date Title
ECSP066826A (es) Inhibidores de integrasa de vih
AR061620A1 (es) Suspensiones acuosas de tmc278
NI201100043A (es) Derivados de dioxa - biciclo [ 3. 2. 1 ] octano - 2, 3, 4 - triol.
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
MY147393A (en) Administration of dipeptidyl peptidase inhibitors
AR050717A1 (es) Composiciones farmaceuticas
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
AR045016A1 (es) Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.
ATE496623T1 (de) Oxcarbazepin-zubereitungen für kontrollierte freisetzung mit sigmoidalem freisetzungsprofil
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
HRP20210945T1 (hr) Formulacije protutijela anti-cd19
UY28873A1 (es) Nuevos compuestos de morfina composiciones y procedimientos de preparación
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
MX393613B (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
ECSP11011001A (es) Composición farmacéutica sólida
AR065034A1 (es) Metodos para prevenir y tratar trastornos neurodegenerativos
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
AR064185A1 (es) Composiciones y metodos para tratar las convulsiones
AR048587A1 (es) Composiciones quimicamente estables de 4-hidroxitamoxifeno
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
AR040134A1 (es) Formulacion para la administracion parenteral de un bloqueante del canal del na
MX2023010545A (es) Inhibidores de integrinas alfa v beta 6 y alfa v beta 1 y usos de los mismos.
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble

Legal Events

Date Code Title Description
FA Abandonment or withdrawal